Edition:
United Kingdom

Keryx Biopharmaceuticals Inc (KERX.OQ)

KERX.OQ on NASDAQ Stock Exchange Capital Market

3.15USD
21 Sep 2018
Change (% chg)

$0.01 (+0.32%)
Prev Close
$3.14
Open
$3.14
Day's High
$3.18
Day's Low
$3.04
Volume
1,563,645
Avg. Vol
266,438
52-wk High
$8.07
52-wk Low
$2.79

Chart for

About

Keryx Biopharmaceuticals, Inc. is a biopharmaceutical company focused on the development of medicines for people with renal disease. The Company is engaged in the manufacture, development and commercialization of products for use in treating human diseases. Its marketed product, Auryxia (ferric citrate), which is an orally... (more)

Overall

Beta: 5.16
Market Cap(Mil.): $897.75
Shares Outstanding(Mil.): 118.75
Dividend: --
Yield (%): --

Financials

  KERX.OQ Industry Sector
P/E (TTM): -- 85.68 32.76
EPS (TTM): -1.70 -- --
ROI: -108.19 1.79 14.61
ROE: -432.72 3.28 16.33

BRIEF-Keryx Biopharmaceuticals Reports Q1 Loss Per Share Of $0.18

* KERYX BIOPHARMACEUTICALS ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS

10 May 2018

BRIEF-Keryx Biopharmaceuticals Sees Total Revenue For Qtr Ended March 31, 2018 Between $21.0 Mln And $22.5 Mln

* KERYX BIOPHARMACEUTICALS SEES TOTAL REVENUE FOR QUARTER ENDED MARCH 31, 2018 OF BETWEEN $21.0 MILLION AND $22.5 MILLION - SEC FILING

30 Apr 2018

Competitors

  Price Chg
Sanofi SA (SASY.PA) €74.50 -0.17
Fresenius Medical Care AG & Co. KGaA (FMEG.DE) €86.92 -1.06
Shire PLC (SHP.L) 4,569.00 +60.00
Shire PLC (3159084.L) -- --

Earnings vs. Estimates